Abstract
Hematopoietic cell transplantation (HCT) activity in China was surveyed to assess its current status. A record number of HCTs (21 884: 16 631 allogeneic (76%) and 5253 autologous (24%)) were reported by 76 centers in China between 1 January 2008 and 30 June 2016. HCT trends included continued growth in transplant activity, a continued rapid increase in haploidentical donors (HID), and slower growth for unrelated donors, matched-related donors (MRD) and cord blood transplantation (CBT). The proportion of HID HCT among allogeneic HCTs increased from 29.6% (313/1062) in 2008 to 48.8% (1939/3975) in 2015, even 51.7% (1157/2237) in the first half of 2016. During this time frame, the proportion of MRD HCTs among allogeneic HCTs decreased from 48.1% (511/1062) to 33.0% (332/3975). The proportion of unrelated donor HCTs among allogeneic HCTs decreased from 20.4 (216/1062) to 13.6% (540/3975). The proportion of CBTs among allogeneic HCTs was increased from 2.1% (22/1062) to 4.2% (184/3975). HCTs have been increasing continuously for all indications except chronic myelogenous leukemia. Severe aplastic anemia is a common HCT indication among non-malignant diseases in China. The number of cases of allogeneic HCT for this disorder has increased annually, from 59 (5.6%) in 2008 to 569 (14.3%) in 2015, even 334 (14.9%) in the first half year in 2016. This survey clearly shows recent trends for HCTs in China.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Experimental Hematology & Oncology Open Access 16 November 2022
-
Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group
Bone Marrow Transplantation Open Access 25 August 2021
-
The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge
Bone Marrow Transplantation Open Access 29 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016; 51: 778–785.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant 2016; 51: 786–792.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476–482.
Yoshimi A, Suzuki R, Atsuta Y, Iida M, Lu DP, Tong W et al. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant 2010; 45: 1682–1691.
Du H, Chen J, Qin M, Fang J, Li Z, Zhu Y et al. Pediatric hematopoietic stem cell transplantation in China: data and trends during 1998–2012. Pediatr Transplant 2015; 19: 563–570.
Stem cell application group of Hematology branch of Chinese Association. Consensus on allogeneic hematopoietic stem cell transplantation in China: indication and condition regimen and donors. Chinese J Hematol 2014; 35: 775–778.
National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Acute Myeloid Leukemia. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Acute Lymphoblastic Leukemia. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Chronic Myeloid Leukemia. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Myelodysplastic Syndromes. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978–985.
Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH et al. The superiority of haploidentical related stem cell transplantation to chemotherapy alone as post-remission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119: 5584–5590.
Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H et al. MRD-directed risk stratification treatment may improve outcomes of t (8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013; 121: 4056–4062.
Qin YZ, Xu LP, Chen H, Jiang Q, Wang Y, Jiang H et al. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leuk Lymphoma 2015; 56: 3116–3123.
Wang Y, Huang XJ . Haploidentical transplantation for the treatment of intermediate- or high-risk acute myeloid leukemia in first complete remission: guideline and practice. Chinese J Hematol 2016; 37: 721–724.
Yan CH, Jiang Q, Wang J, Xu LP, Liu DH, Jiang H et al. Superior survival of unmanipulated haploidentical HSCT compared with chemotherapy alone used as post-remission therapy in adult standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant 2014; 20: 1314–1321.
Sun YQ, Wang J, Jiang Q, Xu LP, Liu DH, Zhang XH et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL. Bone Marrow Transplant 2015; 50: 20–25.
Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a Biologically Phase III Randomized Study. Clin Cancer Res 2016; 22: 3467–3476.
Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH et al. Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012; 18: 716–721.
Xu ZL, Huang XJ, Liu KY, Chen H, Zhang XH, Han W et al. Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia. Pediatr Transplant 2016; 20: 572–580.
Chen H, Liu KY, Xu LP, Chen YH, Han W, Zhang XH et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2015; 21: 1110–1116.
Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032–3040.
Xu L, Zhu H, Hu J, Wu D, Jiang H, Jiang Q et al. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. Front Med 2015; 9: 304–311.
Jiang H, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014; 49: 1146–1154.
Xu LP, Xu ZL, Zhang XH, Chen H, Chen YH, Han W et al. Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia. Biol Blood Marrow Transplant 2016; 22: 1080–1086.
Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.
Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M et al. Haplo-identical transplantation for acquired severe aplastic anemia in a multi-center prospective study. Br J Haematol 2016; 175: 265–274.
Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol 2017; 10: 25.
Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH et al. Who is the best donor for a related HLA-haplotype-mismatched transplant? Blood 2014; 124: 843–850.
Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol 2015; 8: 84–92.
Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al. Haploidentical vs. identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125: 3956–3962.
Wang Y, Wang HX, Lai YR, Sun ZM, Wu DP, Jiang M et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia 2016; 30: 2055–2063.
Liu DH, Xu LP, Liu KY, Wang Y, Chen H, Han W et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia. Bone Marrow Transplant 2013; 48: 1519–1524.
Ma YR, Huang XJ, Xu ZL, Liu KY, Chen H, Zhang XH et al. Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clin Transplant 2016; 30: 994–1001.
Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I et al. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Acute Leukemia Working Party of the EBMT. Haematologica 2016; 101: e352–e354.
Huang XJ, Xu LP, Liu KY, Liu DH, Wang Y, Chen H et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15: 4777–4783.
Mo XD, Tang BL, Zhang XH, Zheng CC, Xu LP, Zhu XY et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. Int J Cancer 2016; 139: 2106–2115.
Acknowledgements
We sincerely thank all participating centers and their staff. All participating teams are listed in the Appendix. This work was supported by the Key Program of the National Natural Science Foundation of China (Grant No. 81230013), the National Natural Science Foundation of China (Grant No. 81400145), Project TG-2015-003 supported by the Health Science Promotion Project of Beijing and the Beijing Talent fund (No. 2015000021223ZK39).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Xu, LP., Wu, DP., Han, MZ. et al. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016. Bone Marrow Transplant 52, 1512–1518 (2017). https://doi.org/10.1038/bmt.2017.59
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.59
This article is cited by
-
Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients
Bone Marrow Transplantation (2024)
-
Psychological and physical side effects during G-CSF mobilization in related donors of allo-HCT
Annals of Hematology (2024)
-
Epstein–Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation
Annals of Hematology (2023)
-
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Experimental Hematology & Oncology (2022)
-
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes
Bone Marrow Transplantation (2022)